Los Angeles, USA, May 05, 2021 (GLOBE NEWSWIRE) -- T-cell Leukemia Pipeline: Comprehensive Analysis of 15+ Key Players and 15+ Key Therapies
Out of all T-cell Leukemia pipeline therapies, HBI-8000 is set to capture the maximum patient pool owing to its immunomodulatory function.
DelveInsight’s ‘T-cell Leukemia Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the T-cell Leukemia domain.
Some of the key highlights of the T-cell Leukemia Pipeline report:
- T-cell Leukemia Pipeline report offers a comprehensive analysis of 15+ key players and 15+ key therapies.
- Out of all the emerging therapies, HBI-8000 is expected to capture the maximum patient pool owing to its immunomodulatory function. This oral agent targets class I histone deacetylase causing cell cycle arrest and tumor cell death as the mechanism underlying its single-agent activity against lymphoma.
- T-cell Leukemia pipeline comprises ASTX 660 (Otsuka Pharmaceutical) is in phase I/II while Valemetostat and Brentuximab vedotin (Seagen/Takeda) is in Phase II stage of development.
- HUYA Bioscience appears to have an upper edge as its therapy, HBI-8000 which is in the pre-registration phase.
- In April 2021, Shorla Pharma announced that the U.S. Food and Drug Administration (FDA) has accepted the filing application of its oncology drug SH-111 which is designed to treat T-cell Leukemia.
Got queries? Want to know more? Request for Sample @ T-cell Leukemia Emerging Therapies and Forecast
The report lays down a complete coverage of the therapeutics by development stage, product type, and route of administration, molecule type, and MOA type for T-cell Leukemia across the complete product development cycle, including all clinical and non-clinical stages.
The T-cell Leukemia pipeline report puts on the table business opportunities, threats, prospective collaborations, strong competitors, growth strategies, and failed as well as discontinued drugs.
T-cell Leukemia Pipeline Drugs
| Drug | Company | Clinical Phase | MoA | RoA |
| Valemetostat | Daiichi Sankyo | Phase II | Histone-lysine N-methyltransferase inhibitors | Oral |
| BNZ-1 | Bioniz | Phase II | Interleukin receptor antagonists | Intravenous |
| ASTX 660 | Otsuka Pharmaceutical | Phase I/II | Inhibitor of apoptosis protein inhibitors; | Oral |
| Brentuximab vedotin | Seagen / Takeda | Phase II | Apoptosis stimulants | Intravenous |
| HBI-8000 | HUYA Bioscience | Preregistration | Ras protein inhibitors | Oral |
Request for Sample to know more @ T-cell Leukemia Pipeline Analysis, Key Companies and Futuristic Trends
T-cell Leukemia Therapeutic Assessment
The T-cell Leukemia Pipeline report proffers exhaustive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
By Route of Administration
- Intravenous
- Inhalation
- Oral
- Subcutaneous
By Mechanism of Action
- Enhancer of zeste homolog 1 and 2 protein inhibitors
- Histone-lysine N-methyltransferase inhibitors
- Interleukin 15 receptor antagonists
- Interleukin 2 receptor antagonists
- Interleukin 9 receptor antagonists
- 1 Phosphatidylinositol 3 kinase inhibitors
- HDAC 1,2,3, and 10 protein inhibitors
- Mitogen-activated protein kinase inhibitors
By Targets
- Protease
- Multiple Kinase
- Interleukin 15 receptor
- Interleukin 2 receptor
- Interleukin 9 receptor
- Histone-lysine N-methyltransferase
Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions
Scope of the Report
Coverage: Global
Key Players: Daiichi Sankyo; Bioniz; Otsuka Pharmaceutical; Seagen /Takeda; HUYA Bioscience; iCell Gene Therapeutics; Gracell Biotechnology; Ascentage Pharma Group; Celgene Corporation; Shorla Pharma; AVM Biotechnology; Expression Therapeutics; miRagen Therapeutics, and others.
Key T-cell Leukemia Pipeline Therapies: Valemetostat; BNZ-1; ASTX 660; Brentuximab vedotin; HBI-8000; CD4CAR; CD7 UCAR-T cells; APG-115; Romidepsin; SH-111; Cobomarsen; AVM-0703, and others.
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | T-cell Leukemia Overview |
| 4 | T-cell Leukemia Pipeline Therapeutics |
| 5 | T-cell Leukemia Pipeline Therapeutic Assessment |
| 6 | T-cell Leukemia – DelveInsight’s Analytical Perspective |
| 7 | In-depth Commercial T-cell Leukemia Pipeline Assessment |
| 8 | T-cell Leukemia Collaboration Deals |
| 9 | Late Stage T-cell Leukemia Pipeline Products (Phase III and Preregistration) |
| 10 | Mid-Stage T-cell Leukemia Pipeline Products (Phase II) |
| 11 | Pre-clinical and Discovery Stage T-cell Leukemia Pipeline Products |
| 12 | Inactive T-cell Leukemia Pipeline Products |
| 13 | T-cell Leukemia Key Companies |
| 14 | T-cell Leukemia Key Products |
| 15 | T-cell Leukemia Unmet Needs |
| 16 | T-cell Leukemia Market Drivers and Barriers |
| 17 | T-cell Leukemia Future Perspectives and Conclusion |
| 18 | T-cell Leukemia Pipeline Analyst Views |
| 20 | Appendix |
Visit to know more of what’s covered @ T-cell Leukemia Emerging Therapies
Browse through Related Reports
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
DelveInsight’s “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030” report.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline
DelveInsight’s, “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape.
Adult T Cell Leukemia Lymphoma Market
DelveInsight's "Adult T-Cell Leukemia-Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030" report.
Acute Myeloid Leukemia Market
DelveInsight's "Acute Myeloid Leukemia (AML) Market Insights, Epidemiology, and Market Forecast-2030" report.
B-Cell Chronic Lymphocytic Leukemia Market
DelveInsight's "B-Cell Chronic Lymphocytic Leukemia - Market Insights, Epidemiology, and Market Forecast-2030" report.
Hairy Cell Leukemia Market Insight Epidemiology and Market Forecast
DelveInsight's 'Hairy Cell Leukemia (HCL)- Market Insights, Epidemiology and Market Forecast-2028' report.
Bowens Disease Market
DelveInsight's "Bowen's Disease - Market Insights, Epidemiology, and Market Forecast-2030" report.
Buergers Disease Market
DelveInsight's "Buerger’s Disease - Market Insights, Epidemiology, and Market Forecast-2030" report.
Brucellosis Market
DelveInsight's "Brucellosis - Market Insights, Epidemiology, and Market Forecast-2030" report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News